US3120564A
(en)
|
1960-01-13 |
1964-02-04 |
American Cyanamid Co |
Alkenoylamino benzophenones
|
ZA825719B
(en)
|
1981-09-03 |
1983-06-29 |
Recordati Chem Pharm |
Alkanoylanilides
|
JPS58179838A
(ja)
|
1982-04-14 |
1983-10-21 |
Konishiroku Photo Ind Co Ltd |
画像形成方法
|
US5256791A
(en)
|
1992-03-02 |
1993-10-26 |
Pfizer Inc. |
Preparation of intermediates in the synthesis of quinoline antibiotics
|
DE4341403A1
(de)
|
1993-12-04 |
1995-06-08 |
Basf Ag |
N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
|
US5475116A
(en)
|
1994-04-29 |
1995-12-12 |
Pfizer Inc. |
Aza bicyclo[3,1,0]hexane intermediates useful in the synthesis of quinolones
|
JPH0912547A
(ja)
|
1995-06-23 |
1997-01-14 |
Chisso Corp |
ニューキノロン系化合物中間体の製造方法
|
WO1997030030A1
(fr)
|
1996-02-13 |
1997-08-21 |
Chugai Seiyaku Kabushiki Kaisha |
Derives d'indole
|
JPH1072434A
(ja)
*
|
1996-04-08 |
1998-03-17 |
Nissan Chem Ind Ltd |
2,4−置換アニリン誘導体
|
US5968929A
(en)
|
1996-10-30 |
1999-10-19 |
Schering Corporation |
Piperazino derivatives as neurokinin antagonists
|
US6184380B1
(en)
|
1999-01-25 |
2001-02-06 |
Pfizer Inc. |
Process for preparing naphthyridones and intermediates
|
US7019142B2
(en)
|
1998-01-16 |
2006-03-28 |
Pfizer Inc. |
Process for preparing naphthyridones and intermediates
|
US6590118B1
(en)
|
1999-09-29 |
2003-07-08 |
Novo Nordisk A/S |
Aromatic compounds
|
CO5261503A1
(es)
|
2000-02-11 |
2003-03-31 |
Vertex Pharma |
Derivados de piperazina y piperidina
|
DE60119047D1
(de)
*
|
2000-08-31 |
2006-06-01 |
Pfizer |
Phenoxyphenylheterozyklen als Serotonin-Wiederaufnahmehemmer
|
CZ20031013A3
(en)
|
2000-10-19 |
2004-03-17 |
Pfizer Products Inc. |
Bridged piperazine derivatives
|
KR100586138B1
(ko)
|
2001-03-30 |
2006-06-07 |
화이자 프로덕츠 인코포레이티드 |
피리다지논 알도스 리덕타제 저해제
|
EP1417204B1
(en)
*
|
2001-08-15 |
2006-01-18 |
E. I. du Pont de Nemours and Company |
Ortho-heterocyclic substituted aryl amides for controlling invertebrate pests
|
US20040034019A1
(en)
|
2002-08-08 |
2004-02-19 |
Ronald Tomlinson |
Piperazine and piperidine derivatives
|
US20040082641A1
(en)
|
2002-10-28 |
2004-04-29 |
Rytved Klaus Asger |
Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
|
JP2006507359A
(ja)
|
2002-10-28 |
2006-03-02 |
ノボ・ノルデイスク・エー/エス |
心循環器疾患の治療のためのグリコーゲンホスホリラーゼ阻害剤の使用
|
EP2177511A2
(en)
|
2002-12-10 |
2010-04-21 |
Ranbaxy Laboratories Limited |
Process for preparing 3,6-disubstituted azabicyclo derivatives
|
EP1581522B1
(en)
|
2002-12-23 |
2008-02-20 |
Ranbaxy Laboratories Limited |
Flavaxate derivatives as muscarinic receptor antagonists
|
AU2002356369A1
(en)
|
2002-12-23 |
2004-07-14 |
Ranbaxy Laboratories Limited |
Xanthine derivatives as muscarinic receptor antagonists
|
US7488748B2
(en)
|
2003-01-28 |
2009-02-10 |
Ranbaxy Laboratories Limited |
3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
WO2005037216A2
(en)
|
2003-10-14 |
2005-04-28 |
Pfizer Products Inc. |
Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
|
KR20060129021A
(ko)
|
2004-02-18 |
2006-12-14 |
교린 세이야꾸 가부시키 가이샤 |
비시클로아미드 유도체
|
DE602005016929D1
(de)
|
2004-06-22 |
2009-11-12 |
Schering Corp |
Liganden für den cannabinoidrezeptoren
|
DE102004039280A1
(de)
*
|
2004-08-13 |
2006-02-23 |
Merck Patent Gmbh |
1,5-Diphenyl-pyrazole
|
MX2007002136A
(es)
|
2004-09-01 |
2007-04-02 |
Pfizer Prod Inc |
Antagonistas amino azabiciclicos del receptor 3 de la histamina.
|
EP1828174A1
(en)
|
2004-11-19 |
2007-09-05 |
Ranbaxy Laboratories Limited |
Azabicyclic muscarinic receptor antagonists
|
CN1944398A
(zh)
|
2005-01-11 |
2007-04-11 |
中国医学科学院药物研究所 |
新的苯甲酰胺类化合物及其制法和药物用途
|
ES2520015T3
(es)
|
2005-04-08 |
2014-11-11 |
Pfizer Products Inc. |
[3.1.0]Heteroaril amidas bicíclicas como inhibidores de transporte de glicina de tipo 1
|
US20090124600A1
(en)
|
2005-04-19 |
2009-05-14 |
Layton Mark E |
N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists
|
RU2007145434A
(ru)
|
2005-05-10 |
2009-06-20 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Бициклические производные в качестве модуляторов ионных каналов
|
GB0510204D0
(en)
|
2005-05-19 |
2005-06-22 |
Chroma Therapeutics Ltd |
Enzyme inhibitors
|
WO2007029086A2
(en)
|
2005-09-05 |
2007-03-15 |
Ranbaxy Laboratories Limited |
Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-iv inhibitors
|
RU2008119323A
(ru)
|
2005-10-19 |
2009-11-27 |
Рэнбакси Лабораториз Лимитед (In) |
Фармацевтические композиции мускаринового рецептора
|
US7560551B2
(en)
|
2006-01-23 |
2009-07-14 |
Amgen Inc. |
Aurora kinase modulators and method of use
|
WO2008010061A2
(en)
|
2006-07-17 |
2008-01-24 |
Glenmark Pharmaceuticals S.A. |
3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
|
GB2454615A
(en)
|
2006-07-21 |
2009-05-13 |
Lupin Ltd |
Antidiabetic azabicyclo (3.1.0) hexan compounds
|
US20100056496A1
(en)
|
2006-09-04 |
2010-03-04 |
Naresh Kumar |
Muscarinic receptor antagonists
|
EP2129660A2
(en)
|
2006-12-19 |
2009-12-09 |
Pfizer Products Inc. |
Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
|
WO2008104869A1
(en)
|
2007-02-26 |
2008-09-04 |
Pfizer Products Inc. |
Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
|
WO2008117229A1
(en)
|
2007-03-23 |
2008-10-02 |
Ranbaxy Laboratories Limited |
Muscarinic receptor antagonists
|
PA8802501A1
(es)
|
2007-10-31 |
2009-06-23 |
Janssen Pharmaceutica Nv |
Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno, hidrolasa
|
WO2009152027A1
(en)
|
2008-06-12 |
2009-12-17 |
Merck & Co., Inc. |
5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for mark inhibition
|
NZ592425A
(en)
|
2008-10-29 |
2013-04-26 |
Celgene Corp |
Isoindoline compounds for use in the treatment of cancer
|
US9149465B2
(en)
|
2009-05-18 |
2015-10-06 |
Infinity Pharmaceuticals, Inc. |
Isoxazolines as inhibitors of fatty acid amide hydrolase
|
AR076687A1
(es)
|
2009-05-18 |
2011-06-29 |
Infinity Pharmaceuticals Inc |
Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen
|
WO2012012314A1
(en)
|
2010-07-23 |
2012-01-26 |
Merck Sharp & Dohme Corp. |
Novel pyrrolidine derived beta 3 adrenergic receptor agonists
|
US8772277B2
(en)
|
2011-08-04 |
2014-07-08 |
Takeda Pharmaceutical Company Limited |
Nitrogen-containing heterocyclic compound
|
US9527830B2
(en)
|
2011-09-16 |
2016-12-27 |
Merck Sharp & Dohme Corp. |
Inhibitors of the renal outer medullary potassium channel
|
TWI566701B
(zh)
|
2012-02-01 |
2017-01-21 |
日本農藥股份有限公司 |
芳烷氧基嘧啶衍生物及包含該衍生物作為有效成分的農園藝用殺蟲劑及其使用方法
|
US9777002B2
(en)
|
2012-11-29 |
2017-10-03 |
Merck Sharp & Dohme Corp. |
Inhibitors of the renal outer medullary potassium channel
|
CN105188705A
(zh)
|
2013-03-13 |
2015-12-23 |
密歇根大学董事会 |
包含噻吩并嘧啶和噻吩并吡啶化合物的组合物及其使用方法
|
EP2970242B1
(en)
|
2013-03-14 |
2017-09-06 |
Novartis AG |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
KR101556318B1
(ko)
|
2013-05-15 |
2015-10-01 |
한국과학기술연구원 |
칼슘이온 채널 조절제로서 유효한 6-피라졸일아미도-3-치환된 아자바이사이클로[3.1.0]헥산 유도체
|
WO2014199164A1
(en)
|
2013-06-12 |
2014-12-18 |
Ampla Pharmaceuticals, Inc. |
Diaryl substituted heteroaromatic compounds
|
AR105889A1
(es)
|
2015-09-03 |
2017-11-22 |
Actelion Pharmaceuticals Ltd |
Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
|
EP3353156B1
(en)
|
2015-09-23 |
2021-11-03 |
The General Hospital Corporation |
Tead transcription factor autopalmitoylation inhibitors
|
US20170158702A1
(en)
|
2015-12-02 |
2017-06-08 |
Kyras Therapeutics, Inc. |
Multivalent ras binding compounds
|
KR20180094923A
(ko)
|
2015-12-24 |
2018-08-24 |
교와 핫꼬 기린 가부시키가이샤 |
α, β 불포화 아미드 화합물
|
UA123109C2
(uk)
|
2016-05-31 |
2021-02-17 |
К'Єзі Фармачеутічі С.П.А. |
Сполуки імідазолону як інгібітори нейтрофіл-еластази людини
|
CN109561682B
(zh)
|
2016-06-27 |
2021-05-11 |
牧牛研究所株式会社 |
包含异噁唑啉环的吡啶类化合物及其作为除草剂的用途
|
NZ750265A
(en)
|
2016-08-23 |
2021-03-26 |
Recurium Ip Holdings Llc |
Methods for cross coupling
|
CN110506039A
(zh)
|
2016-10-11 |
2019-11-26 |
阿尔维纳斯股份有限公司 |
用于雄激素受体靶向降解的化合物和方法
|
WO2018102751A1
(en)
|
2016-12-02 |
2018-06-07 |
Quentis Therapeutics, Inc. |
Ire1 small molecule inhibitors
|
CA3062294A1
(en)
*
|
2017-05-03 |
2018-11-08 |
Vivace Therapeutics, Inc. |
Non-fused tricyclic compounds
|
US20200095236A1
(en)
|
2017-05-10 |
2020-03-26 |
Forge Therapeutics, Inc. |
Antibacterial compounds
|
JP7221202B2
(ja)
|
2017-06-23 |
2023-02-13 |
協和キリン株式会社 |
α、β不飽和アミド化合物
|
US11192865B2
(en)
*
|
2017-08-21 |
2021-12-07 |
Vivace Therapeutics, Inc. |
Benzosulfonyl compounds
|
TWI793151B
(zh)
|
2017-08-23 |
2023-02-21 |
瑞士商諾華公司 |
3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
|
TW201920108A
(zh)
|
2017-09-25 |
2019-06-01 |
日商武田藥品工業有限公司 |
N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
|
US10287222B1
(en)
|
2017-10-20 |
2019-05-14 |
Uop Llc |
Process and apparatus for desorbent recovery
|
WO2019089670A1
(en)
|
2017-11-01 |
2019-05-09 |
Bristol-Myers Squibb Company |
Alkene compounds as farnesoid x receptor modulators
|
PE20201170A1
(es)
|
2017-11-01 |
2020-10-28 |
Bristol Myers Squibb Co |
Compuestos biciclicos en puente como moduladores del receptor farnesoide x
|
EP3720430A4
(en)
|
2017-12-06 |
2021-05-05 |
Vivace Therapeutics, Inc. |
BENZOCARBONYL COMPOUNDS
|
AU2019216492A1
(en)
|
2018-02-02 |
2020-08-20 |
Vanderbilt University |
Antagonists of the muscarinic acetylcholine receptor M4
|
WO2019195959A1
(en)
|
2018-04-08 |
2019-10-17 |
Cothera Biosciences, Inc. |
Combination therapy for cancers with braf mutation
|
WO2019204505A2
(en)
|
2018-04-18 |
2019-10-24 |
Theras, Inc. |
K-ras modulators with a vinyl sulfonamide moiety
|
EP3802543A1
(en)
|
2018-05-31 |
2021-04-14 |
F. Hoffmann-La Roche AG |
Therapeutic compounds
|
WO2020051099A1
(en)
|
2018-09-03 |
2020-03-12 |
Genentech, Inc. |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
EP3856735B1
(en)
|
2018-10-05 |
2023-09-06 |
New York University |
Fused bicyclic heterocycles as therapeutic agents
|
AU2019362788A1
(en)
|
2018-10-15 |
2021-04-15 |
Dana-Farber Cancer Institute, Inc. |
Transcriptional enhanced associate domain (TEAD) transcription factor inhibitors and uses thereof
|
CA3115526A1
(en)
|
2018-10-15 |
2020-04-23 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
|
WO2020087063A1
(en)
|
2018-10-26 |
2020-04-30 |
The Trustees Of Indiana University |
Compounds and methods to attenuate tumor progression and metastasis
|
BR112021015783A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
|
WO2020190774A1
(en)
|
2019-03-15 |
2020-09-24 |
The General Hospital Corporation |
Novel small molecule inhibitors of tead transcription factors
|
US20220153722A1
(en)
|
2019-04-04 |
2022-05-19 |
Dana-Farber Cancer Institute, Inc. |
Cdk2/5 degraders and uses thereof
|
EP3958861A4
(en)
|
2019-04-23 |
2023-05-03 |
Dana-Farber Cancer Institute, Inc. |
DEGRADERS OF CYCLIN DEPENDENT KINASE 12 (CDK12) AND USES THEREOF
|
BR112021024108A2
(pt)
|
2019-05-31 |
2022-03-22 |
Ikena Oncology Inc |
Inibidores de tead e usos dos mesmos
|
MX2021014441A
(es)
|
2019-05-31 |
2022-01-06 |
Ikena Oncology Inc |
Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
|
KR20220101138A
(ko)
|
2019-11-13 |
2022-07-19 |
제넨테크, 인크. |
치료적 화합물 및 사용 방법
|
KR20220119671A
(ko)
|
2019-12-24 |
2022-08-30 |
다나-파버 캔서 인스티튜트 인크. |
전사 증진 회합 도메인 (tead) 전사 인자 억제제 및 그의 용도
|
JP2023516645A
(ja)
|
2020-03-04 |
2023-04-20 |
ジェネンテック, インコーポレイテッド |
Tead阻害剤としてのヘテロ二官能性分子
|
EP4164752A1
(en)
|
2020-06-03 |
2023-04-19 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of transcriptional enhanced associate domain (tead) and uses thereof
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2022120355A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead degraders and uses thereof
|
KR20230131189A
(ko)
|
2020-12-02 |
2023-09-12 |
이케나 온콜로지, 인코포레이티드 |
Tead 억제제 및 이의 용도
|
WO2022159986A1
(en)
|
2021-01-25 |
2022-07-28 |
Ikena Oncology, Inc. |
Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer
|